

## ESOPHAGEAL CANCER CANCER DE L'ŒSOPHAGE

### MAY 8 AND 9, 2009



#### SESSION 1 | Chair: André Duranceau

- 8:00 Welcome and introduction  
**Pasquale Ferraro** (Montréal, Québec)  
Chair, Thoracic Surgery Division
- 8:30 Epidemiology and pathogenesis of esophageal cancer in 2009  
**A.H. Hölscher** (Cologne, Germany)
- 8:45 Esophagogastric cancer services in the United Kingdom: from nihilism to specialism  
**M. Griffin** (Newcastle-Upon-Tyne, UK)
- 9:00 Changes in practice in the last three decades  
**M.K. Ferguson** (Chicago, IL)
- 9:15 A uniform database for management and reporting  
**T.W. Rice** (Cleveland, OH)
- 9:30 Panel Discussion
- Coffee

#### SESSION 2 | Chair: Gilles Beauchamp

- 10:15 Radiologic evaluation of esophageal cancer  
**L. Samson** (Montréal, Québec)
- 10:30 Endoscopy and EUS  
**M. Liberman** (Montréal, Québec)
- 10:45 Prospective assessment of PET staging  
**J.J. van Lanschot** (Amsterdam)
- 11:00 Sentinel node assessment in esophageal cancer  
**M. Griffin** (Newcastle-Upon-Tyne, UK)
- 11:15 Panel Discussion
- Lunch

#### SESSION 3 | Chair: Pasquale Ferraro

- 1:30 The new TNM staging  
**T.W. Rice** (Cleveland, OH)
- 1:45 Methodology of lymph node assessment  
**G.G. Jamieson** (Adelaide, Australia)
- 2:00 Lymph node resection radicality vs numbers  
**A.F. Hölscher** (Cologne, Germany)
- 2:15 Genetics and molecular staging  
**J.J. van Lanschot** (Amsterdam)
- 2:30 Panel Discussion
- Coffee

#### SESSION 4 | Chair: Éric Fréchette


- 3:15 Chemotherapy alone as definitive treatment  
**J.P. Ayoub** (Montréal, Québec)
- 3:30 Pros and cons of neoadjuvant treatment  
**J.J. van Lanschot** (Amsterdam)
- 3:45 The complete endoscopic responder  
**A.F. Hölscher** (Cologne, Germany)
- 4:00 Is there an indication for restaging after neoadjuvant therapy?  
**J. Martin** (Montréal, Québec)
- 4:15 Panel Discussion



Thoracic Surgery Division

**André Duranceau**  
**Pasquale Ferraro**  
**Jocelyne Martin**  
**Moishe Liberman**

Tel. : 514-890-8000, ext.: 26253  
e-mail: andre.duranceau@umontreal.ca



#### SESSION 5 | Chair: Jocelyne Martin

- 8:30 The esophageal remnant after gastric interposition  
**A. Duranceau** (Montréal, Québec)
- 8:45 Quality of life after esophagectomy  
**D. Ouellette** (Montréal, Québec)
- 9:00 Ischemic conditioning of the stomach for esophageal replacement  
**A.F. Hölscher** (Cologne, Germany)
- 9:15 Standardization of perioperative clinical pathways  
**D. Maziak** (Ottawa, Ontario)
- 9:30 Panel Discussion
- Coffee

#### SESSION 6 | Chair: Rosaire Vaillancourt

- 10:15 Risk profiling in esophageal cancer patients  
**M. Ferguson** (Chicago, IL)
- 10:30 The Amsterdam/Rotterdam risk assessment model  
**J.J. van Lanschot** (Amsterdam)
- 10:45 High grade dysplasia and esophageal cancer: role of mucosal resection  
**M. Liberman** (Montréal, Québec)
- 11:00 Early esophageal cancer: role of surgery  
**T.W. Rice** (Cleveland, OH)
- 11:15 Panel Discussion
- Lunch

#### SESSION 7 | Chair: Moishe Liberman

- 1:30 Trans hiatal vs trans thoracic resection  
**J.J. van Lanschot** (Amsterdam)
- 1:45 Minimally invasive esophagectomy  
**M. Ferguson** (Chicago, IL)
- 2:00 Radical esophagectomy for cancer  
**M. Griffin** (Newcastle-Upon-Tyne, UK)
- 2:15 Reporting mortality after an esophagectomy  
**G.G. Jamieson** (Adelaide, Australia)
- 2:30 Panel Discussion
- Coffee

#### SESSION 8 | Chair: Jocelyn Grégoire

- 3:15 Palliating esophageal cancer prosthesis vs radio and/or chemotherapy  
**G. Beauchamp** (Montréal, Québec)
- 3:30 Reflux prevention after esophagectomy  
**G.G. Jamieson** (Adelaide, Australia)
- 3:45 Management of anastomotic and mediastinal leaks  
**M. Griffin** (Newcastle-Upon-Tyne, UK)
- 4:00 Managing the failed reconstruction  
**M. Ferguson** (Chicago, IL)
- 4:15 Panel Discussion
- Closure

The official language of the Symposium is English

Approved for C.M.E. credits  
Université de Montréal